타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 3개 · 임상 갱신 필요 3개 · 차세대 보드에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||
|---|---|---|---|
Overview Program | Stelara (ustekinumab) | Skyrizi (risankizumab-rzaa) | Tremfya (guselkumab) |
Overview Company | Johnson & Johnson | AbbVie | Johnson & Johnson |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | IL-12 / IL-23 (p40) | IL-23 p19 | IL-23 p19 |
Overview Indication | Psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis | Plaque psoriasis, PsA, Crohn's disease, ulcerative colitis | Plaque psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease |
Overview Phase | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | Novel therapeutic avenues, including TYK2 and HDAC inhibitors, as well as nanotechnology-based delivery systems, show encoura | Novel therapeutic avenues, including TYK2 and HDAC inhibitors, as well as nanotechnology-based delivery systems, show encoura | Leaving IL-12 intact preserves Th1 antimicrobial immunity while shutting down the Th17 axis, which is why durability is high and infection signals are low. |
Positioning Known limitation | IL-23 axis escape, anti-drug antibodies, and non-IL-12/23 inflammation. | IL-17 independent disease and immunogenicity. | Anti-drug antibodies are rare; non-IL-23-driven fibrostenotic disease does not respond. |
Positioning Development positioning | — | — | 1L–2L biologic across dermatology, rheumatology, and gastroenterology |
MoA Mechanism | Ustekinumab binds the p40 subunit shared by IL-12 and IL-23, preventing their interaction with IL-12Rβ1 receptor and downstream Th1/Th17 differentiation and cytokine production. | Risankizumab selectively binds IL-23 p19 subunit, blocking IL-23 interaction with IL-23R and downstream Th17 pathway (IL-17A/F, IL-22). | Neutralizes IL-23 by binding p19, blocking IL-23R signaling and downstream Th17/Th22 differentiation, IL-17 production, and tissue inflammation in skin, joints, and gut mucosa. |
MoA Biomarker | biomarkers but require external validation in independent cohorts | PASI, sPGA, IBD endoscopic scores. | PASI/IGA in psoriasis, ACR20 in PsA, endoscopic improvement and fecal calprotectin in IBD. |
Toxicology Species | Cynomolgus monkey, Mouse | Cynomolgus monkey | Pig |
Toxicology Major finding | Infections, reversible posterior leukoencephalopathy syndrome (rare), hypersensitivity. | Upper respiratory infections, headache, fatigue; low TB reactivation vs TNF class. | Upper respiratory infection, headache, and injection-site reactions dominate. Serious infection and malignancy signals have stayed low across long-term psoriasis follow-up. |
Toxicology CRS | N/A | N/A | N/A |
Clinical Safety signal | Infections, reversible posterior leukoencephalopathy syndrome (rare), hypersensitivity. | Upper respiratory infections, headache, fatigue; low TB reactivation vs TNF class. | Upper respiratory infection, headache, and injection-site reactions dominate. Serious infection and malignancy signals have stayed low across long-term psoriasis follow-up. |
Clinical Program phase | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 3개 · 임상 갱신 필요 3개 · 차세대 보드에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||
|---|---|---|---|
Overview Program | Stelara (ustekinumab) | Skyrizi (risankizumab-rzaa) | Tremfya (guselkumab) |
Overview Company | Johnson & Johnson | AbbVie | Johnson & Johnson |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | IL-12 / IL-23 (p40) | IL-23 p19 | IL-23 p19 |
Overview Indication | Psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis | Plaque psoriasis, PsA, Crohn's disease, ulcerative colitis | Plaque psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease |
Overview Phase | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | Novel therapeutic avenues, including TYK2 and HDAC inhibitors, as well as nanotechnology-based delivery systems, show encoura | Novel therapeutic avenues, including TYK2 and HDAC inhibitors, as well as nanotechnology-based delivery systems, show encoura | Leaving IL-12 intact preserves Th1 antimicrobial immunity while shutting down the Th17 axis, which is why durability is high and infection signals are low. |
Positioning Known limitation | IL-23 axis escape, anti-drug antibodies, and non-IL-12/23 inflammation. | IL-17 independent disease and immunogenicity. | Anti-drug antibodies are rare; non-IL-23-driven fibrostenotic disease does not respond. |
Positioning Development positioning | — | — | 1L–2L biologic across dermatology, rheumatology, and gastroenterology |
MoA Mechanism | Ustekinumab binds the p40 subunit shared by IL-12 and IL-23, preventing their interaction with IL-12Rβ1 receptor and downstream Th1/Th17 differentiation and cytokine production. | Risankizumab selectively binds IL-23 p19 subunit, blocking IL-23 interaction with IL-23R and downstream Th17 pathway (IL-17A/F, IL-22). | Neutralizes IL-23 by binding p19, blocking IL-23R signaling and downstream Th17/Th22 differentiation, IL-17 production, and tissue inflammation in skin, joints, and gut mucosa. |
MoA Biomarker | biomarkers but require external validation in independent cohorts | PASI, sPGA, IBD endoscopic scores. | PASI/IGA in psoriasis, ACR20 in PsA, endoscopic improvement and fecal calprotectin in IBD. |
Toxicology Species | Cynomolgus monkey, Mouse | Cynomolgus monkey | Pig |
Toxicology Major finding | Infections, reversible posterior leukoencephalopathy syndrome (rare), hypersensitivity. | Upper respiratory infections, headache, fatigue; low TB reactivation vs TNF class. | Upper respiratory infection, headache, and injection-site reactions dominate. Serious infection and malignancy signals have stayed low across long-term psoriasis follow-up. |
Toxicology CRS | N/A | N/A | N/A |
Clinical Safety signal | Infections, reversible posterior leukoencephalopathy syndrome (rare), hypersensitivity. | Upper respiratory infections, headache, fatigue; low TB reactivation vs TNF class. | Upper respiratory infection, headache, and injection-site reactions dominate. Serious infection and malignancy signals have stayed low across long-term psoriasis follow-up. |
Clinical Program phase | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts |
추천 비교
추천 비교